Skinvisible, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 23, 2020 at 04:58 pm EST
Share
Skinvisible, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was USD 4,183 compared to USD 11,295 a year ago. Operating loss was USD 118,622 compared to USD 136,925 a year ago. Net loss was USD 409,759 compared to USD 348,742 a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.12 a year ago. For the nine months, sales was USD 21,592 compared to USD 1,100 a year ago. Operating loss was USD 261,376 compared to USD 422,313 a year ago. Net loss was USD 1.152 million compared to USD 1.274 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.44 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
SKINVISIBLE, INC. 
